Overview: The TRP superfamily of cation channels (nomenclature agreed by NC-IUPHAR; Clapham et al., 2003), whose founder member is the Drosophila Trp channel, can be divided, in mammals, into six families: TRPC, TRPM, TRPV, TRPA, TRPP and TRPML based on amino acid homologies (see Clapham, 2003; Delmas et al., 2004a; Moran et al., 2004; Montell, 2005; Nilius and Voets, 2005; Pedersen et al., 2005; Owsianik et al., 2006a; Minke, 2006; Ramsey et al., 2006; Venkatachalam and Montell, 2007). TRP subunits contain six putative transmembrane domains and assemble as homo- or hetero-tetramers to form cation-selective channels with varied permeation properties (reviewed by Owsianik et al., 2006b). The TRPC (‘Canonical’) and TRPM (‘Melastatin’) subfamilies consist of seven and eight different channels respectively (i.e. TRPC1–TRPC7 and TRPM1–TRPM8). The TRPV (‘Vanilloid’) subfamily comprises six members (TRPV1–TRPV6) whereas the TRPA (Ankyrin) subfamily has only one mammalian member (TRPA1). The TRPP (‘Polycystin’) and TRPML (‘Mucolipin’) families are not fully characterized, and the tables below are thus incomplete. Established, or potential, physiological functions of the individual members of the TRP families are discussed in detail in the recommended reviews. The established, or potential, involvement of TRP channels in disease is reviewed in Kiselyov et al. (2007a) and Nilius et al. (2007) together with a special edition of Biochemica et Biophysica Acta on the subject edited by Nilius (2007).
TRPC family: Members of the TRPC subfamily (reviewed by Freichel et al., 2005; Pedersen et al., 2005; Putney, 2005; Ambudkar and Ong, 2007; Abramowitz and Birnbaumer, 2009; Beech et al., 2009; Birnbaumer, 2009; Kiselyov and Patterson, 2009), on the basis of sequence homology and similarities in function, fall into four subfamilies: TRPC1, TRPC2, TRPC3/6/7 and TRPC4/5. TRPC2 (not tabulated) is a pseudogene in man. All TRPC channels have been proposed to act as store-operated channels, activated by depletion of intracellular calcium stores (reviewed by Pedersen et al., 2005; Ambudkar and Ong, 2007; Potier and Trebak, 2008; Salido et al., 2009; Yuan et al., 2009), but this is highly controversial. However, there is conflicting evidence that TRPC1, TRPC4/5 and TRPC3/6/7 can function as receptor-operated channels that are mostly insensitive to store depletion (reviewed by Plant and Schaefer, 2003; Trebak et al., 2007).
| Nomenclature | TRPC1 | TRPC3 | TRPC4 |
| Other names | TRP1 | TRP3 | TRP4, CCE1 |
| Ensembl ID | ENSG00000144935 | ENSG00000138741 | ENSG00000100991 |
| Activators | Gq/11-coupled receptors, membrane stretch, PLCγ stimulation, intracellular Ins(1,4,5)P3 (disputed), thapsigargin (disputed), activated by NO-mediated cysteine S-nitrosylation | Gq/11-coupled receptors, OAG (independent of PKC), PLCγ stimulation, Ins(1,4,5)P3 (disputed) and thapsigargin (disputed), probably activated by Ca2+ (disputed), activated by PI(4,5)2 | Gq/11-coupled receptors, GTPγS (requires extracellular Ca2+), Ins(1,4,5)P3 (disputed) and thapsigargin (disputed), activated by F2v peptide and calmidazolium by antagonism of Ca2+-calmodulin, activated by NO-mediated cysteine S-nitrosylation, potentiated by extracellular protons |
| Blockers | Gd3+, La3+, 2-APB, SKF96365, Ca2+-calmodulin inhibits, GsMTx-4 | Gd3+, La3+, Ni2+, 2-APB, SKF96365, KB-R7943, BTP2 | La3+ (at mM concentrations – augments in µM range), 2-APB, SKF96365 |
| Functional characteristics | γ = 16 pS (estimated by fluctuation analysis), conducts mono- and divalent cations non-selectively; monovalent cation current suppressed by extracellular Ca2+; non-rectifying, or mildly inwardly rectifying; non-inactivating | γ = 66 pS; conducts mono- and divalent cations non-selectively (PCa/PNa = 1.6); monovalent cation current suppressed by extracellular Ca2+; dual (inward and outward) rectification; relieved of inhibition by Ca2+-calmodulin by IP3 receptors, IP3 receptor derived peptide (F2v) and calmidazolium; inhibited by PKG-mediated phosphorylation | γ = 30–41 pS, conducts mono- and divalent cations non-selectively (PCa/PNa = 1.1–7.7); dual (inward and outward) rectification, inhibited by PI(4,5)2 |
| Nomenclature | TRPC5 | TRPC6 | TRPC7 |
| Other names | TRP5, CCE2 | TRP6 | TRP7 |
| Ensembl ID | ENSG00000072315 | ENSG00000137672 | ENSG00000069018 |
| Activators | Gq/11-coupled receptors, Ins(1,4,5)P3, GTPγS (potentiated by extracellular Ca2+), adenophostin A and thapsigargin (disputed), La3+ (10 µM), Gd3+ (0.1 mM), elevated [Ca2+]o (5–20 mM), lysophosphatidylcholine (independent of G protein signalling), activated by NO-mediated cysteine S-nitrosylation (disputed), potentiated by extracellular protons | Gq/11-coupled receptors, membrane stretch, AlF4-, GTPγS [but not Ins(1,4,5)P3], 20-HETE, OAG (independent of PKC) and inhibition of DAG lipase with RHC80267, synergistic stimulation by Gq/11-coupled receptors and OAG, activated by Ca2+ (disputed), AlF4, flufenamate, hyperforin | Gq/11-coupled receptors. OAG (independent of PKC), thapsigargin (disputed) |
| Blockers | La3+ (at mM concentrations – augments in µM range), 2-APB, SKF96365, KB-R7943, BTP2, flufenamic acid, chlorpromazine | La3+ (IC50 ≅ 6 µM), Gd3+, amiloride,,SKF96365, 2-APB, ACA, KB-R7943, ML-9 (independent of MLCK), extracellular protons, GsMTx-4 | La3+, SKF96365, amiloride, 2-APB |
| Functional characteristics | γ = 41–63 pS; conducts mono-and divalent cations non-selectively (PCa/PNa = 1.8–9.5); dual rectification (inward and outward) as a homomer, outwardly rectifying when expressed with TRPC1 or TRPC4; inhibited by xestospongin C, activated, or inhibited, by PI(4,5)2 | γ = 28–37 pS; conducts mono- and divalent cations with a preference for divalents (PCa/PNa = 4.5–5.0); monovalent cation current suppressed by extracellular Ca2+ and Mg2+, dual rectification (inward and outward), or inward rectification, enhanced by flufenamate; positively modulated by phosphorylation mediated by Src protein tyrosine kinases, activated, or inhibited, by PI(4,5)2 | γ = 25–75 pS; conducts mono- and divalent cations with a preference for divalents (PCa/PCs = 5.9); modest outward rectification (monovalent cation current recorded in the absence of extracellular divalents); monovalent cation current suppressed by extracellular Ca2+ and Mg2+, inhibited by intracellular Ca2+ via calmodulin, activated, or inhibited, by PI(4,5)2 |
A comprehensive listing of G protein-coupled receptors that activate TRPC channels is given in Abramowitz and Birnbaumer (2009). In addition to the specific agents listed in the table several members of the TRPC family are modulated by lipid factors such as arachidonic acid and its metabolites, sphingosine-1-phosphate, cholesterol and gangliosides (reviewed by Beech et al., 2009). Hetero-oligomeric complexes of TRPC channels and their association with proteins to form signalling complexes are detailed in Ambudkar and Ong (2007) and Kiselyov et al. (2007b).
TRPM family: Members of the TRPM subfamily (reviewed by Fleig and Penner, 2004; Harteneck, 2005; Pedersen et al., 2005), on the basis of sequence homology, fall into four groups: TRPM1/3, TRPM2/8, TRPM4/5 and TRPM6/7. TRPM1 may exist as five splice variants and is involved in normal melanocyte pigmentation (Oancea et al., 2009). TRPM2 functions as a sensor of redox status in cells (reviewed by Eisfeld and Lückhoff, 2007). TRPM3 (reviewed by Oberwinkler and Phillipp, 2007) exists as multiple splice variants four of which (mTRPM3α1, mTRPM3α2, hTRPM3a and hTRPM31325) have been characterized and found to differ significantly in their biophysical properties. A splice variant of TRPM4 (i.e. TRPM4b) and TRPM5 are molecular candidates for endogenous calcium-activated cation channels (Nilius et al., 2003; Liman, 2007; Vennekens and Nilius, 2007). TRPM4 has been shown to be an important regulator of Ca2+ entry in to mast cells (Vennekens et al., 2007) and dendritic cell migration (Barbet et al., 2008). TRPM5 in taste receptor cells of the tongue appears essential for the transduction of sweet, amino acid and bitter stimuli (Liman, 2007). TRPM6 and 7 combine channel and enzymatic activities (‘chanzymes’) and are involved in Mg2+ homeostasis (Schmitz et al., 2003; Voets et al., 2004a; reviewed by Bodding, 2007; Penner and Fleig, 2007). TRPM8 is a channel activated by cooling and pharmacological agents evoking a ‘cool’ sensation. TRPM8(−/−) mice display pronounced deficits in the thermosensation of cold temperatures (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007).
| Nomenclature | TRPM1 | TRPM2 | TRPM3 |
| Other names | LTRPC1, Melastatin | (TRPC7, LTRPC2) | LTRPC3 |
| Ensembl ID | ENSG00000134160 | ENSG00000142185 | ENSG00000083067 |
| Activators | Constitutively active | Intracellular ADP ribose (ADPR) and cyclic ADPR (cADPR); agents producing reactive oxygen (e.g. H2O2) and nitrogen (e.g. GEA3162) species; intracellular Ca2+ via calmodulin, potentiated by arachidonic acid, activated by heat ∼35°C | Small constitutive activity, activated by pregnenolone sulphate and nifedipine, current augmented by strong depolarization, stimulated by store depletion with thapsigargin, stimulated by cell swelling, activated by D-erythro-sphingosine and dihydrosphingosine |
| Blockers | La3+, Gd3+ | Clotrimazole, miconazole, econazole, flufenamic acid, ACA, 2-APB, activation by ADPR and cADPR blocked by AMP (IC50 = 10–70 µM) and 8-bromo-cADPR respectively | La3+, Gd3+, 2-APB, intracellar Mg2+, extracellular Na+ (TRPM3α2 only) |
| Functional characteristics | Conducts mono- and divalent cations non-selectively, outwardly rectifying | γ = 52–60 pS at negative potentials, 76 pS at positive potentials; conducts mono- and divalent cations non-selectively (PCa/PNa = 0.6–0.7); non-rectifying; inactivation at negative potentials; activated by oxidative stress probably via PARP-1, PARP inhibitors reduce activation by oxidative stress, activation inhibited by suppression of APDR formation by glycohydrolase inhibitors | TRPM31235: γ = 83 pS (Na+ current), 65 pS (Ca2+ current); conducts mono- and divalent cations non-selectively (PCa/PNa = 1.6) TRPM3α1: selective for monovalent cations (PCa/PCs ∼ 0.1) TRPM3α2: conducts mono- and divalent cations non-selectively (PCa/PCs = 1–10) Outwardly rectifying (magnitude varies between spice variants) |
| Nomenclature | TRPM4 | TRPM5 | TRPM6 |
| Other names | LTRPC4 | TRP-T | – |
| Ensembl ID | ENSG00000130529 | ENSG00000070985 | ENSG00000119121 |
| Activators | Decavanadate, whole cell current transiently activated by intracellular Ca2+ (EC50 = 0.3–20 µM), activated by membrane depolarization (V½ = −20–+60 mV dependent upon conditions) in the presence of elevated [Ca2+]I, heat (Q10 = 8.5 at +25 mV between 15 and 25°C), positively modulated by PI(4,5)P2, enhanced by BTP2 | Gq/11-coupled receptors, Ins(1,4,5)P3, transiently activated by intracellular Ca2+ (EC50 = 700–840 nM), activated by membrane depolarization (V½ = 0–+120 mV dependent upon conditions), heat (Q10 = 10.3 at −75 mV between 15 and 25°C), stimulated by PI(4,5)P2 | Constitutively active, activated by reduction of intracellular Mg2+, potentiated by extracellular protons and 2APB |
| Blockers | Intracellular nucleotides (ATP4−, ADP, AMP, AMP-PNP – IC50 range 1.3–19 µM) and adenosine (IC50 = 630 µM); intracellular spermine (IC50 = 35–61 µM) and flufenamic acid (IC50 = 2.8 µM), extracellular clotrimazole and 9-phenanthrol | Intracellular spermine (IC50 = 37 µM) and flufenamic acid (IC50 = 24 µM), extracellular protons (IC50 = 630 nM) (not inhibited by ATP4−) | Ruthenium red (voltage-dependent block, IC50 = 100 nM at –120 mV), inward current mediated by monovalent cations blocked by Ca2+ (IC50 = 4.8–5.4 µM) and Mg2+ (IC50 = 1.1–3.4 µM) |
| Functional characteristics | γ = 23 pS (within the range 60–+60 mV); permeable to monovalent cations; impermeable to Ca2+; strong outward rectification; slow activation at positive potentials, rapid deactivation at negative potentials, deactivation blocked by decavanadate | γ = 15–25 pS; conducts monovalent cations selectively (PCa/PNa = 0.05); strong outward rectification; slow activation at positive potentials, rapid inactivation at negative potentials; activated and subsequently desensitized by [Ca2+]I, desensitization relieved by short chain synthetic PtdIns(4,5)P2 | γ = 40–87 pS; permeable to mono- and divalent cations with a preference for divalents (Mg2+ > Ca2+; PCa/PNa = 6.9), conductance sequence Zn2+ > Ba2+ > Mg2+ = Ca2+ = Mn2+ > Sr2+ > Cd2+ > Ni2+; strong outward rectification abolished by removal of extracellular divalents, inhibited by intracellular Mg2+ (IC50 = 0.5 mM) and ATP |
| Nomenclature | TRPM7 | TRPM8 |
| Other names | TRP-PLIK, Chak1, MagNum, MIC | CMR1, TRP-p8 |
| Ensembl ID | ENSG00000092439 | ENSG000000144481 |
| Activators | Gs-coupled receptors via elevated cAMP and activation of PKA; potentiated by intracellular ATP; positively modulated by PI(4,5)P2, potentiated by extracellular protons | Depolarization (V½ ≅ +50 mV at 15°C), cooling (<22–26°C), PI(4,5)P2; WS-12, (-)-menthol, icilin (requires intracellular Ca2+ as a cofactor for full agonist activity, blocks activation by menthol); agonist activities are temperature-dependent and potentiated by cooling |
| Blockers | Spermine (permeant blocker), carvacrol, La3+, Mg2+, 2-APB | Clotrimazole, BCTC, capsazepine, 2-APB, La3+, ACA, anandamide, NADA, linoleic acid, cannabinoids (e.g. cannabidiol, THC); insensitive to ruthenium red |
| Functional characteristics | γ = 40–105 pS at negative and positive potentials respectively; conducts mono- and divalent cations with a preference for monovalents (PCa/PNa = 0.34); conductance sequence Ni2+ > Zn2+ > Ba2+ = Mg2+ > Ca2+ = Mn2+ > Sr2+ > Cd2+; outward rectification, decreased by removal of extracellular divalent cations; inhibited by intracellular Mg2+, Ba2+, Sr2+, Zn2+, Mn2+ and Mg.ATP (disputed); inhibited by Gi-coupled receptors activated by membrane stretch and intracellular alkalinization; sensitive to osmotic gradients, activated, or inhibited, by PI(4,5)2 | γ = 40–83 pS at positive potentials; conducts mono- and divalent cations non-selectively (PCa/PNa = 1.0–3.3); pronounced outward rectification; demonstrates densensitization to chemical agonists and adaptation to a cold stimulus in the presence of Ca2+; modulated by lysophospholipids and PUFAs |
A truncated TRPM2 isoform (TRPM2-S), generated by alternative splicing, prevents activation of the full-length protein (TRPM2-L) by H2O2 when co-expressed with the latter, which is important for apoptosis and cell death. TRPM4 exists as multiple splice variants: data listed are for TRPM4b. The sensitivity of TRPM4b and TRPM5 to activation by [Ca2+]i demonstrates a pronounced and time-dependent reduction following excision of inside-out membrane patches (Ullrich et al., 2005). The V½ for activation of TRPM4 and TRPM5 demonstrates a pronounced negative shift with increasing temperature. Activation of TRPM8 by depolarization is strongly temperature-dependent via a channel-closing rate that decreases with decreasing temperature. The V½ is shifted in the hyperpolarizing direction both by decreasing temperature and by exogenous agonists, such as menthol (Voets et al., 2004b) whereas antagonists produce depolarizing shifts in V½ (Mälkiäet al., 2007). The V½ for the native channel is far more positive than that of heterologously expressed TRPM8 (Mälkiäet al., 2007). It should be noted that menthol and structurally related compounds can elicit release of Ca2+ from the endoplasmic reticulum independent of activation of TRPM8 (Mahieu et al., 2007). Intracellular pH modulates activation of TRPM8 by cold and icilin, but not menthol (Andersson et al., 2004).
TRPV family: Members of the TRPV family (reviewed by Vennekens et al., 2008; Vriens et al., 2009), on the basis of structure and function, comprise four groups: TRPV1/2, TRPV3, TRPV4 and TRPV5/6. TRPV1-4 are thermosensitive, non-selective cation channels that can additionally be activated by numerous chemicals (reviewed by Benham et al., 2003, Nilius et al., 2004; Pedersen et al., 2005; Starowicz et al., 2007; Szallasi et al., 2007; Vriens et al., 2009). Members of the TRPV family function as tetrameric complexes. Numerous splice variants of TRPV1 have been described, some of which act in a dominant negative manner when co-expressed with TRPV1 (see Pringle et al., 2007; Szallasi et al., 2007). Under physiological conditions, TRPV5 and TRPV6 are calcium-selective channels involved in the absorption and reabsorption of calcium across intestinal and kidney tubule epithelia (reviewed by Wissenbach and Niemeyer, 2007; de Groot et al., 2008).
| Nomenclature | TRPV1 | TRPV2 | TRPV3 |
| Other names | VR1, vanilloid/capsaicin receptor, OTRPC1 | VRL-1, OTRPC2, GRC | – |
| Ensembl ID | ENSG00000043316 | ENSG00000154039 | ENSG00000167723 |
| Activators | Depolarization (V½ ≅ 0 mV at 35°C), noxious heat (>43°C at pH 7.4), extracellular protons (pEC50 = 5.4 at 37°C), capsaicin, resiniferatoxin, vanillotoxins, phenylaceytlrivanil, olvanil, anandamide, camphor, allicin, some eicosanoids [e.g. 12-(S)-HPETE, 15-(S)-HPETE, 5-(S)-HETE, leukotriene B4], NADA, 2-APB, DPBA, activated by NO-mediated cysteine S-nitrosylation | Noxious heat (>53°C, rodent, not human), probenecid, 2-APB (rodent, not human), DPBA, cannabidiol, THC | Depolarization (V½ ∼ +80 mV, reduced to more negative values following heat stimuli), heat (23–39°C, temperature threshold influenced by ‘thermal history’ of the cell), 6-tert-butyl-m-cresol, carvacrol, eugenol, thymol, camphor, menthol, incensole acetate, 2-APB, DPBA, activated by NO-mediated cysteine S-nitrosylation |
| Blockers (IC50) | Ruthenium red (0.09–0.22 µM), 5′-iodoresiniferatoxin (3.9 nM), 6-iodo-nordihydrocapsaicin (10 nM), BCTC (6–35 nM), capsazepine (40–280 nM), A-425619 (5 nM), A-778317 (5 nM), AMG517 (0.9 nM), AMG628 (3.7 nM), JNJ17203212 (65 nM), JYL1421 (9.2 nM), SB366791 (18 nM), SB452533, SB-705498 (3–6 nM) | Ruthenium red (0.6 µM), SKF96365, amiloride, TRIM, La3+ | Ruthenium red (<1 µM), DPTHF (6–10 µM) |
| Probes (KD) | [3H]-A778317 (3.4 nM), [3H]-resiniferatoxin, [125I]-resiniferatoxin | – | – |
| Functional characteristics | γ = 35 pS at –60 mV; 77 pS at +60 mV, conducts mono- and divalent cations with a selectivity for divalents (PCa/PNa = 9.6); conducts the charged local anaesthetic QX-314; allows proton influx contributing to intracellular acidification in acidic media; voltage- and time-dependent outward rectification; potentiated by ethanol; activated/potentiated/up-regulated by PKC stimulation; extracellular acidification facilitates activation by PKC; desensitization inhibited by PKA; activated, or inhibited, by PI(4,5)2, inhibited by Ca2+/calmodulin; cooling reduces vanilloid-evoked currents; may be tonically active at body temperature | Conducts mono- and divalent cations (PCa/PNa = 0.9–2.9); dual (inward and outward) rectification; current increases upon repetitive activation by heat; translocates to cell surface in response to IGF-1 to induce a constitutively active conductance, translocates to the cell surface in response to membrane stretch | γ = 197 pS at = +40–+80 mV, 48 pS at negative potentials; conducts mono- and divalent cations; outward rectification; potentiated by arachidonic acid |
| Nomenclature | TRPV4 | TRPV5 | TRPV6 |
| Other names | VRL-2, OTRPC4, VR-OAC, TRP12 | ECaC, ECaC1, CaT2, OTRPC3 | ECaC2, CaT1, CaT-L |
| Ensembl ID | ENSG00000111199 | ENSG00000127412 | ENSG00000165125 |
| Activators | Constitutively active, heat (>24–32°C), cell swelling (not membrane stretch or reduced internal ionic strength), responses to heat increased in hypoosmotic solutions and vice versa, bisandrographolide A, 4α-PDD, PMA, epoxyeicosatrieonic acids; sensitized by PKC, activated by NO-mediated cysteine S-nitrosylation | Constitutively active (with strong buffering of intracellular Ca2+) | Constitutively active (with strong buffering of intracellular Ca2+), potentiated by 2-APB |
| Blockers | Ruthenium red (voltage-dependent block), La3+, Gd3+ | Ruthenium red (IC50 = 121 nM), econazole, miconazole, Pb2+ = Cu2+ = Gd3+ > Cd2+ > Zn2+ > La3+ > Co2+ > Fe2+; Mg2+ | Ruthenium red (IC50 = 9 µM), Cd2+, Mg2+, La3+ |
| Functional characteristics | γ = ∼60 pS at –60 mV, ∼90–100 pS at +60 mV; conducts mono- and divalent cations with a preference for divalents (PCa/PNa = 6–10); dual (inward and outward) rectification; potentiated by intracellular Ca2+ via Ca2+/calmodulin; inhibited by elevated intracellular Ca2+ via an unknown mechanism (IC50 = 0.4 µM); potentiated by Src family tyrosine kinase | γ = 59–78 pS for monovalent ions at negative potentials, conducts mono- and divalents with high selectivity for divalents (PCa/PNa > 107); voltage- and time-dependent inward rectification; inhibited by intracellular Ca2+ promoting fast inactivation and slow down-regulation; feedback inhibition by Ca2+ reduced by calcium binding protein 80-K-H; inhibited by extracellular and intracellular acidosis; up-regulated by 1,25-dihydrovitamin D3 | γ = 58–79 pS for monovalent ions at negative potentials, conducts mono- and divalents with high selectivity for divalents (PCa/PNa > 130); voltage- and time-dependent inward rectification; inhibited by intracellular Ca2+ promoting fast and slow inactivation; gated by voltage-dependent channel blockade by intracellular Mg2+; slow inactivation due to Ca2+-dependent calmodulin binding; phosphorylation by PKC inhibits Ca2+-calmodulin binding and slow inactivation; up-regulated by 1,25-dihydroxyvitamin D3 |
Activation of TRPV1 by depolarization is strongly temperature-dependent via a channel opening rate that increases with increasing temperature. The V½ is shifted in the hyperpolarizing direction both by increasing temperature and by exogenous agonists (Voets et al., 2004b). Capsaicin, resiniferatoxin and olvanil are exogenous agonists of TRPV1 that possess a vanilloid group, but the receptor is also activated by endogenous lipids that lack a vanilloid moiety (see Starowicz et al., 2007; Vriens et al., 2009). Adenosine has been proposed to be an endogenous antagonist of TRPV1 (Puntambekar et al., 2004). TRPV3 can co-assemble with TRPV1 to form a functional hetero-oligomer (Smith et al., 2002). The sensitivity of TRPV4 to heat, but not 4α-PDD, is lost upon patch excision. TRPV4 is activated by anandamide and arachidonic acid following P450 epoxygenase-dependent metabolism to 5′,6′-epoxyeicosatrienoic acid (reviewed by Nilius et al., 2004). Activation of TRPV4 by cell swelling, but not heat, or phorbol esters, is mediated via the formation of epoxyeicosatrieonic acids. Phorbol esters bind directly to TRPV4. TRPV5 preferentially conducts Ca2+ under physiological conditions, but in the absence of extracellular Ca2+, conducts monovalent cations. Single-channel conductances listed for TRPV5 and TRPV6 were determined in divalent cation-free extracellular solution. Ca2+-induced inactivation occurs at hyperpolarized potentials when Ca2+ is present extracellularly. Single-channel events cannot be resolved (probably due to greatly reduced conductance) in the presence of extracellular divalent cations. Measurements of PCa/PNa for TRPV5 and TRPV6 are dependent upon ionic conditions due to anomalous mole fraction behaviour. Blockade of TRPV5 and TRPV6 by extracellular Mg2+ is voltage-dependent. Intracellular Mg2+ also exerts a voltage-dependent block that is alleviated by hyperpolarization and contributes to the time-dependent activation and deactivation of TRPV6-mediated monovalent cation currents. TRPV5 and TRPV6 differ in their kinetics of Ca2+-dependent inactivation and recovery from inactivation. TRPV5 and TRPV6 function as homo- and hetero-tetramers.
TRPA family: The TRPA family currently comprises one mammalian member, TRPA1 (reviewed by Garcia-Anoveros and Nagata, 2007), which in some (Story et al., 2003; Bandell et al., 2004; Sawada et al., 2007; Karashima et al., 2009), but not other (Jordt et al., 2004; Nagata et al., 2005), studies is activated by noxious cold. One study suggests that activation of TRPA1 is secondary to a cold-induced elevation of [Ca2+]i (Zurborg et al., 2007), but this has recently been refuted (Karashima et al., 2009). Additionally, TRPA1 has been proposed to be a component of a mechanosensitive transduction channel of vertebrate hair cells (Corey et al., 2004; Nagata et al., 2005), but TRPA1(−/−) mice demonstrate no impairment in hearing, or vestibular function (Bautista et al., 2006; Kwan et al., 2006). TRPA1 acts as a nociceptor channel (Nagata et al., 2005; Bautista et al., 2006; Kwan et al., 2006). TRPA1 presents the unusual structural feature of 14 ankyrin repeats within the intracellular N-terminal domain.
| Nomenclature | TRPA1 |
| Other names | ANKTM1, p120, TRPN1 |
| Ensembl ID | ENSG00000104321 |
| Activators | Cooling (<17°C) (disputed), (-)-menthol (1–100 µM), thymol (1–100 µM), isothiocyanates, THC, cinnamaldehyde, allicin, carvacrol, formalin, 4-hydroxy-2-nonenal, methyl-p-hydroxybenzoate, URB597, cyclopentone prostaglandins, 1,4-dihydropyridines, isoflurane, desflurane, propofol, etomidate |
| Blockers | Ruthenium red (IC50 < 1–3 µM), menthol (1 mM, mouse, not human), Gd3+, gentamicin, HC-030031 |
| Functional characteristics | γ = 87–100 pS; conducts mono- and divalent cations non-selectively (PCa/PNa = 0.84); outward rectification; inactivates in response to prolonged cooling; sensitizes in response to repeated applications of cinnamaldehyde; activated by OAG and arachidonic acid downstream of receptor-mediated PLC stimulation; sensitized by PAR2 activation possibly due to relief of inhibition by PI(4,5)P2; activated by elevated intracellular Ca2+. |
Icilin activates TRPM8 in addition to TRPA1 (Jordt et al., 2004). Activation of TRPA1 by isothiocyanates and other reactive agents occurs via covalent modification of cysteine residues within the cytoplasmic N-terminus of the channel (Hinman et al., 2006; Macpherson et al., 2007). Activation of TRPA1 by pungent chemicals has been claimed to require intracellular polyphosphates (Kim and Cavanaugh, 2007). TRPA1 is potently activated by intracellular zinc (EC50 = 8 nM) (Andersson et al., 2009; Hu et al., 2009).
TRPML family: The TRPML family (see Qian and Noben-Trauth, 2005; Zeevi et al., 2007; Puertollano and Kiselyov, 2009) consists of three mammalian members (TRPML1-3). TRPML channels are probably restricted to intracellular vesicles and mutations in the gene (MCOLN1) encoding TRPML1 (mucolipin-1) are the cause of the neurodegenerative disorder mucolipidosis type IV (MLIV) in man. TRPML1 is a cation-selective ion channel that is important for sorting/transport of endosomes in the late endocytotic pathway and specifically fusion between late endosome-lysosome hybrid vesicles. TRPML2 (MCLN2) remains to be functionally characterized in detail. TRPML3 is important for hair cell maturation, stereocilia maturation and intracellular vesicle transport. A naturally occurring gain of function mutation in TRPML3 (i.e. A419P) results in the varitint waddler (Va) mouse phenotype (reviewed by Qian and Noben-Trauth, 2005; Nilius et al., 2007).
| Nomenclature | TRPML1 | TRPML2 | TRPML3 |
| Other names | MCLN1, mucolipin-1 (ML1) | MCLN2 | |
| Ensembl ID | ENSG00000090674 | ENSG00000153898 | ENSG00000055732 |
| Activators | TRPML1Va: constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification) | TRPML2Va: constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification) | TRPML3va: constitutively active, current inhibited by extracellular acidification (equivalent to intralysosomal acidicification) Wild-type TRPML3: activated by Na+-free extracellular (extracytosolic) solution and membrane depolarization, current inhibited by extracellular acidification (equivalent to intralysosomal acidicification) |
| Blockers | – | – | Gd3+ |
| Functional characteristics | TRPML1Va: γ = 40 pS and 76–86 pS at very negative holding potentials with Fe2+ and monovalent cations as charge carriers respectively; conducts Na+ ≅ K+ > Cs+ and divalent cations (Ba2+ > Mn2+ > Fe2+ > Ca2+ > Mg2+ > Ni2+ > Co2+ > Cd2+ > Zn2+ >> Cu2+) but not Fe3+, impermeable to protons; monovalent cation flux suppressed by divalent cations (e.g. Ca2+, Fe2+); inwardly rectifying | TRPML1Va: conducts Na+; monovalent cation flux suppressed by divalent cations; inwardly rectifying | TRPML3Va: γ = 49 pS at very negative holding potentials with monovalent cations as charge carrier; conducts Na+ > K+ > Cs+ with maintained current in the presence of Na+, conducts Ca2+ and Mg2+, but not Fe2+, impermeable to protons; inwardly rectifying Wild-type TRPML3: γ = 59 pS at negative holding potentials with monovalent cations as charge carrier; conducts Na+ > K+ > Cs+ and Ca2+ (PCa/PK ≅ 350), slowly inactivates in the continued presence of Na+ within the extracellular (extracytosolic) solution; outwardly rectifying |
Data in the table are for TRPML proteins mutated (i.e. TRPML1Va, TRPML2Va and TRPML3Va) at loci equivalent to TRPML3 A419P to allow plasma membrane expression when expressed in HEK-293 cells and subsequent characterization by patch-clamp recording (Grimm et al., 2007; Kim et al., 2007; Xu et al., 2007; Dong et al., 2008; Nagata et al., 2008). Data for wild-type TRPML3 are also tabulated (Kim et al., 2007; 2008; Xu et al., 2007; Nagata et al., 2008). It should be noted that alternative methodologies, particularly in the case of TRPML1, have resulted in channels with differing biophysical characteristics (reviewed by Puertollano and Kiselyov, 2009).
TRPP family: The TRPP family (reviewed by Delmas et al., 2004a; Delmas, 2005; Giamarchi et al., 2006; Witzgall, 2007) subsumes the polycystins that are divided into two structurally distinct groups, polycystic kidney disease 1-like (PKD1-like) and polycystic kidney disease 2-like (PKD2-like). Members of the PKD1-like group, in mammals, include PKD1 (recently reclassified as TRPP1), PDKREJ, PKD1L1, PKD1L2 and PKD1L3. The PKD2-like members comprise PKD2, PKD2L1 and PKD2L2, which have renamed TRPP2, TRPP3 and TRPP5 respectively (Moran et al., 2004). PKDREJ (ENSG00000130943), PKD1L1 (ENSG00000158683), PKD1L2 (ENSMUS00000034416), PKD1L3 (ENSG00000187008) and TRPP5 (ENSG00000078795) are not listed in the table due to lack of functional data. Similarly, TRPP1 (ENSG00000008710) is also omitted because although one study (Babich et al., 2004) has reported the induction of a cation conductance in CHO cells transfected with TRPP1, there is no unequivocal evidence that TRPP1 is a channel per se and in other studies (e.g. Hanaoka et al., 2000; Delmas et al., 2004b) TRPP1 is incapable of producing currents. Conversely, TRPP1 has been demonstrated to constitutively activate G proteins and subsequently c-Jun N-terminal kinase. Unlike other TRP channels, TRPP1 contains 11 putative transmembrane domains and an extremely large and complex extracellular N-terminal domain that contains several adhesive domains. There is good evidence that TRPP1 and TRPP2 physically couple to act as a signalling complex (Delmas et al., 2004a). The association of TRPP1 and TRPP2 suppresses the G protein stimulating activity of TRPP1 and also the constitutive channel activity of TRPP2. Antibodies directed against the REJ domain of TRPP1 alleviate such mutual inhibition, simultaneously enhancing TRPP2 channel gating and the activation of G proteins by TRPP1.
| Nomenclature | TRPP2 | TRPP3 |
| Other names | Polycystin-2 (PC2), polycystic kidney disease 2 (PKD2) | Polycystic kidney disease 2-like 1 protein (PKD2L1) |
| Ensembl ID | ENSG00000118762 | ENSG00000107593 |
| Activators | Constitutive activity, suppressed by co-expression of TRPP1 | Low constitutive activity, enhanced by membrane depolarization; changes in cell volume affect voltage-dependent gating (increased channel opening probability with cell swelling) |
| Blockers (IC50) | La3+, Gd3+, amiloride | Phenamil (0.14 µM), benzamil (1.1 µM), EIPA (10.5 µM), amiloride (143 µM), La3+, Gd3+, flufenamate |
| Functional characteristics | γ = 123–177 pS (with K+ as charge carrier); PNa/PK = 0.14–1.1; conducts both mono- and divalent cations; probably associates with TRPV4; also associates with cortactin and cadherin via TRPP1; channel activity increased by association with α-actinin | γ = 105–137 pS (outward conductance) 184–399 pS (inward conductance), conducts mono- and divalent cations with a preference for divalents (PCa/PNa = 4.0–4.3); steady state currents rectify outwardly, whereas instantaneous currents show strong inward rectification; activated and subsequently inactivated by intracellular Ca2+ (human, but not mouse); inhibited by extracellular acidification and potentiated by extracellular alkalization |
Data in the table are extracted from Delmas et al. (2004a), Dai et al. (2007) and Shimizu et al. (2009). Broadly similar single-channel conductance, mono- and divalent cation selectivity and sensitivity to blockers are observed for TRPP2 co-expressed with TRPP1 (Delmas et al., 2004b). TRPP2 is important for cilia movement, development of the heart, skeletal muscle and kidney. TRPP2 is also likely to act as an intracellular Ca2+ release channel. Ca2+, Ba2+ and Sr2+ permeate TRPP3, but reduce inward currents carried by Na+. Mg2+ is largely impermeant and exerts a voltage-dependent inhibition that increases with hyperpolarization. TRPP3 plays a role in retinal development.
Glossary
Abbreviations:
- 2-APB
2-amino ethoxyphenylborate
- 4α-PDD
4α-phorbol 12,13-didecanoate
- 5-(S)-HETE
5-(S)-hydroxyeicosatetraenoic acid
- 12-(S)-HPETE and 15-(S)-HPETE
12- and 15-(S)-hydroperoxyeicosatetraenoic acids
- 20-HETE
20-hydroxyeicosatetraenoic acid
- A-425619
1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)urea
- A-778317
1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea
- ACA
N-(p-amylcinnamoyl)anthranilic acid
- AMG517
N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl}-acetamide
- AMG628
(R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide
- BCTC
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide
- BTP2
4-methy-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide
- DPBA
diphenylboronic anhydride
- DPTHF
diphenyltetrahydrofuran
- GEA3162
1,2,3,4-oxatriazolium-5-amino-3-(3,4-dichlorophenyl)-chloride
- JNJ17203212
4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide
- JYL1421
N-(4-tert-butylbenzyl)-N′-[3-fluoro-4-(methylsulfonylamino)benzyl]thiourea
- KB-R7943
2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulfonate
- ML-9
1-(5-chloronaphtalene-1-sulphonyl)homopiperazine
- NADA
N-arachidonyl dopamine
- OAG
1-oleoyl-2-acetyl-sn-glycerol
- PMA
phorbol 12 myristate 13-acetate
- RHC80267
1,6-di[O-(carbamoyl)cyclohexanone oxime]hexane
- SB366791
N-(3-methoxyphenyl)-4-chlorocinnamide
- SB705498
N-(2-bromophenyl)-N′-[((R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea
- SDZ249665
1-[4-(2-amino-ethoxy)-3-methoxy-benzyl]-3-(4-tert-butyl-benzyl)-urea
- SKF96265
1-(β-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenethyl)-1H-imidazole hydrochloride
- THC
Δ9-tetrahydrocannabinol
- TRIM
1-(2-(trifluoromethyl)phenyl) imidazole
- URB597
3′-carbamoylbiphenyl-3-yl cyclohexylcarbamate
- WS-12
2-isopropyl-5-methyl-cyclohexanecarboxylic acid (4-methoxy-phenyl)-amide
Further Reading
Abramowitz J, Birnbaumer L (2009). Physiology and pathophysiology of canonical transient receptor potential channels. FASEB J23: 297–328.
Ambudkar IS, Ong HL (2007). Organisation and function of TRPC channelosomes. Pflügers Arch455: 187–200.
Ambudkar IS, Ong HL, Liu X, Bandyopadhyay B, Cheng KT (2007). TRPC1: the link between functionally distinct store-operated calcium channels. Cell Calcium42: 213–223.
Beech DJ, Bahnasi YM, Dedman AM, Al-Shawaf E (2009). TRPC channel lipid specificity and mechanisms of lipid regulation. Cell Calcium45: 583–588.
Benham CD, Gunthorpe MJ, Davis JB (2003). TRPV channels as temperature sensors. Cell Calcium33: 479–487.
Birnbaumer L (2009). The TRPC class of ion channels: a critical review of their roles in slow, sustained increases in intracellular Ca2+ concentrations. Annu Rev Pharmacol Toxicol49: 395–426.
Bodding M (2007). TRPM6: A Janus-like protein. Handb Exp Pharmacol179: 299–311.
Clapham DE (2003). TRP channels as cellular sensors. Nature426: 517–24.
Clapham DE, Montell C, Schultz G, Julius D. (2003). International Union of Pharmacology. XLIII. Compendium of Voltage-gated ion channels. Transient receptor potential channels. Pharmacol Rev55: 591–596.
Delmas P (2005). Polycystins: polymodal receptor/ion-channel cellular sensors. Pflügers Arch451: 264–276.
Delmas P, Padilla F, Osorio N, Coste B, Raoux M, Crest M (2004a). Polycystins, calcium signaling, and human diseases. Biochem Biophys Res Commun322: 1374–1383.
Dhaka A., Viswanath V, Patapoutian A. (2006). Trp ion channels and temperature sensation. Annu Rev Neurosci29: 135–161.
Eisfeld A, Lückhoff J (2007). TRPM2. Handb Exp Pharmacol179: 237–252.
Fleig A, Penner R (2004). The TRPM ion channel subfamily: molecular, biophysical and functional features. Trends Pharmacol Sci25: 633–639.
Freichel M, Vennekens R, Olausson J, Stolz S, Philipp SE, Weißgerber P et al. (2005). Functional role of TRPC proteins in native systems: implications from knockout and knock-down studies. J. Physiol567: 59–66.
Garcia-Anoveros J, Nagata K (2007). TRPA1. Handb Exp Pharmacol179: 347–362.
Giamarchi A, Padilla F, Coste B, Raoux M, Crest M, Honore E et al. (2006). The versatile nature of the calcium-permeable cation channel TRPP2. EMBO Rep7: 787–793.
de Groot T, Bindels RJ, Hoenderop JG (2008). TRPV5: an ingeniously controlled calcium channel. Kidney Int74: 1241–1246.
Harteneck C (2005). Function and Pharmacology of TRPM cations channels. Naunyn Schmiedebergs Arch Pharmacol371: 307–314.
Jordt SE, McKemy DD, Julius D (2003). Lessons from peppers and peppermint: the molecular logic of thermosensation. Curr Opin Neurobiol13: 487–492.
Kiselyov K, Patterson RL (2009). The integrative function of TRPC channels. Front Biosci14: 45–58.
Kiselyov K, Shin DM, Kim JY, Yuan JP, Muallem S. (2007b) TRPC channels: interacting proteins. Handb Exp Pharmacol179:559–574.
Kiselyov K, Soyombo A, Muallem S (2007a). TRPpathies. J Physiol578: 641–653.
Liman ER (2007). TRPM5 and taste transduction. Handb Exp Pharmacol179: 287–298.
McKemy, DD (2005). How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain1: 16.
Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, Patapoutian A, Story GM (2006). More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci32: 335–343.
Minke B (2006). TRP channels and Ca2+ signaling. Cell Calcium40: 261–275.
Montell C (2004). Exciting trips for TRPs. Nat Cell Biol6: 690–692.
Montell C (2005). The TRP superfamily of cation channels. Science STKE272: re3
Moran MM, Xu H, Clapham DE (2004). TRP ion channels in the nervous system. Curr Opin Neurobiol14: 362–369.
Nilius B (ed.) (2007). TRP channels in disease. Biochim Biophys Acta1772: 805–1032.
Nilius B, Voets T (2005). A TR(I)P through a world of multifunctional cation channels. Pflügers Arch451: 1–10.
Nilius B, Droogmans G, Wondergem R (2003). Transient receptor potential channels in endothelium: solving the calcium entry puzzle? Endothelium10: 5–15.
Nilius B Vriens J, Prenen J, Droogmans G, Voets T (2004). TRPV4 calcium channel: a paradigm for gating diversity. Am J Physiol286: C195–C205.
Nilius B, Talavera K, Owsianik G, Prenen J, Droogmans G, Voets T. (2005). Gating of TRP channels: a voltage connection? J Physiol567: 35–44.
Nilius B, Owsianik G, Voets T, Peters JA (2007). Transient receptor potential channels meet phosphoinositides. EMBO J27: 2809–2816.
Nilius B, Owsianik G, Voets T (2008). Transient receptor potential (TRP) cation channels in disease. Physiol Rev87: 165–217.
Oberwinkler J, Phillipp SE (2007). TRPM3. Handb Exp Pharmacol179: 253–267.
Owsianik G, D'hoedt D, Voets T, Nilius B (2006a). Structure-function relationship of the TRP channel superfamily. Rev Physiol Biochem Pharmacol156: 61–90.
Owsianik G, Talavera G, Voets, Nilius B (2006b). Permeation and selectivity of TRP channels. Annu Rev Physiol68: 685–717.
Patapoutian A, Peier AP, Story G, Viswanath V (2003). ThermoTRPs and beyond: Mechanisms of temperature sensation. Nat Rev Neurosci4: 529–539.
Pedersen SF, Owsianik G, Nilius B (2005). TRP Channels: an overview. Cell Calcium38: 233–252.
Penner R, Fleig A (2007). The Mg2+ and Mg2+-nucleotide-regulated channel-kinase TRPM7. Handb Exp Pharmacol179: 313–328.
Plant TD, Schaefer M. (2003). TRPC4 and TRPC5: receptor-operated Ca2+-permeable non-selective cation channels. Cell Calcium33: 441–450.
Potier M, Trebak M (2008). New developments in the signalling mechanisms of the store-operated calcium entry pathway. Pflügers Arch457: 405–415.
Pringle SC, Matta JA, Ahern GP (2007). Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol179: 153–169.
Puertollano R, Kiselyov K (2009). TRPMLs: in sickness and in health. Am J Physiol Renal Physiol296: F1245–F1254.
Putney J (ed.) (2004). Mammalian TRP Channels as Molecular Targets – Novartis Foundation Symposium No. 258. Wiley: Europe, pp. 1–286.
Putney JW (2005). Physiological mechanisms of TRPC activation. Pflügers Arch451: 29–34.
Qian F, Noben-Trauth K (2005). Cellular and molecular function of mucolipins (TRPML) and polycystin 2 (TRPP2). Pflügers Arch451: 277–285.
Ramsey IS, Delling M, Clapham DE (2006). An introduction to TRP channels. Annu Rev Physiol68: 619–647.
Rychkov G, Barritt GJ (2007). TRPC1 Ca2+-permeable channels in animal cells. Handb Exp Pharmacol179: 23–52.
Salido GM, Sage SO, Rosado JA (2009). TRPC channels and store-operated Ca2+ entry. Biochim Biophys Acta1793: 223–230.
Starowicz K, Nigam S, Di Marzo V (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther114:13–33.
Szallasi A, Cortright DN, Blum CA, Eid SR (2007). The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov6: 357–372.
Trebak M, Lemonnier L, Smyth JT, Vazquez G, Putney JW Jr (2007). Phospholipase C-coupled receptors and activation of TRPC channels. Handb Exp Pharmacol179: 593–614.
Venkatachalam K, Montell C (2007). TRP channels. Annu Rev Biochem76: 387–417.
Vennekens R, Nilius B (2007). Insights into TRPM4 function, regulation and physiological role. Handb Exp Pharmacol179: 269–285.
Vennekens R, Owsianik G, Nilius B (2008). Vanilloid transient receptor potential cation channels: an overview. Curr Pharm Des14: 18–31.
Voets T, Nilius B (2003). TRPs make sense. J Membrane Biol192: 1–8.
Voets T, Nilius B (2007). Modulation of TRPs by PIPs. J Physiol582: 939–944.
Voets T, Talavera K, Owsianik G, Nilius B (2005). Sensing with TRP channels. Nature Chem Biol2: 85–92.
Voets T, Owsainik G, Nilius B (2007). TRPM8. Handb Exp Pharmacol179:329–344.
Vriens J, Appendino G, Nilius B (2009). Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol75: 162–1279.
Wissenbach U, Niemeyer BA (2007). TRPV6. Handb Exp Pharmacol179: 221–234.
Witzgall R (2007). TRPP2 channel regulation. Handb Exp Pharmacol179: 363–375.
Yuan JP, Kim MS, Zeng W, Shin DM, Huang G, Worley PF, Muallem S (2009). TRPC channels as STIM1-regulated SOCs. Channels (Austin) 2009 3: 221–225.
Zeevi DA, Frumkin A, Bach G (2007). TRPML and lysosomal function. Biochim Biophys Acta1772: 851–858.
Zitt C, Halaszovich CR, Luckhoff A (2002) The TRP family of cation channels: probing and advancing the concepts on receptor-activated calcium entry. Prog Neurobiol66: 243–264.
Zu MX, Tang J (2004). TRPC channel interactions with calmodulin and IP3 receptors. Novartis Found Symp258: 44–58.
References
- Andersson DA, et al. J Neurosci. 2004;24:5364–5369. doi: 10.1523/JNEUROSCI.0890-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Andersson DA, et al. Proc Natl Acad Sci USA. 2009;106:8374–8379. doi: 10.1073/pnas.0812675106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Babich V, et al. J Biol Chem. 2004;279:25582–25589. doi: 10.1074/jbc.M402829200. [DOI] [PubMed] [Google Scholar]
- Bandell M, et al. Neuron. 2004;41:849–857. doi: 10.1016/s0896-6273(04)00150-3. [DOI] [PubMed] [Google Scholar]
- Barbet G, et al. Nat Immunol. 2008;9:1148–1156. doi: 10.1038/ni.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bautista DM, et al. Cell. 2006;124:1269–1282. doi: 10.1016/j.cell.2006.02.023. [DOI] [PubMed] [Google Scholar]
- Bautista DM, et al. Nature. 2007;448:204–208. doi: 10.1038/nature05910. [DOI] [PubMed] [Google Scholar]
- Colburn RW, et al. Neuron. 2007;54:379–386. doi: 10.1016/j.neuron.2007.04.017. [DOI] [PubMed] [Google Scholar]
- Corey DP, et al. Nature. 2004;432:723–730. doi: 10.1038/nature03066. [DOI] [PubMed] [Google Scholar]
- Dai XQ, et al. Mol Pharmacol. 2007;72:1576–1585. doi: 10.1124/mol.107.037150. [DOI] [PubMed] [Google Scholar]
- Delmas P, et al. FASEB J. 2004b;18:740–742. doi: 10.1096/fj.03-0319fje. [DOI] [PubMed] [Google Scholar]
- Dhaka A, et al. Neuron. 2007;54:371–378. doi: 10.1016/j.neuron.2007.02.024. [DOI] [PubMed] [Google Scholar]
- Dong X-P, et al. Nature. 2008;455:992–997. doi: 10.1038/nature07311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grimm C, et al. Proc Natl Acad Sci USA. 2007;104:19583–19588. doi: 10.1073/pnas.0709846104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hanaoka K, et al. Nature. 2000;408:990–994. doi: 10.1038/35050128. [DOI] [PubMed] [Google Scholar]
- Hinman A, et al. Proc Natl Acad Sci USA. 2006;103:19564–19568. doi: 10.1073/pnas.0609598103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hu H, et al. Nat Chem Biol. 2009;5:183–190. doi: 10.1038/nchembio.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jordt SE, et al. Nature. 2004;427:260–265. doi: 10.1038/nature02282. [DOI] [PubMed] [Google Scholar]
- Karashima Y, et al. Proc Natl Acad Sci USA. 2009;106:1273–1278. doi: 10.1073/pnas.0808487106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim D, Cavanaugh EJ. J Neurosci. 2007;27:6500–6509. doi: 10.1523/JNEUROSCI.0623-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim JK, et al. J Biol Chem. 2007;282:36138–36142. doi: 10.1074/jbc.C700190200. [DOI] [PubMed] [Google Scholar]
- Kim JK, et al. EMBO J. 2008;27:1197–1205. doi: 10.1038/emboj.2008.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kwan KY, et al. Neuron. 2006;50:277–289. doi: 10.1016/j.neuron.2006.03.042. [DOI] [PubMed] [Google Scholar]
- Macpherson LJ, et al. Nature. 2007;445:541–545. doi: 10.1038/nature05544. [DOI] [PubMed] [Google Scholar]
- Mahieu F, et al. J Biol Chem. 2007;282:3325–3336. doi: 10.1074/jbc.M605213200. [DOI] [PubMed] [Google Scholar]
- Mälkiä A, et al. J Physiol. 2007;581:155–174. doi: 10.1113/jphysiol.2006.123059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nagata K, et al. J Neurosci. 2005;25:4052–4061. doi: 10.1523/JNEUROSCI.0013-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nagata K, et al. Proc Natl Acad Sci USA. 2008;105:353–358. doi: 10.1073/pnas.0707963105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nilius B, et al. J. Biol. Chem. 2003;278:30813–30820. doi: 10.1074/jbc.M305127200. [DOI] [PubMed] [Google Scholar]
- Oancea E, et al. Sci Signal. 2009;2(70):ra21. doi: 10.1126/scisignal.2000146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Puntambekar P, et al. J Neurosci. 2004;24:3663–3671. doi: 10.1523/JNEUROSCI.4773-03.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sawada Y, et al. Brain Res. 2007;1160:39–46. doi: 10.1016/j.brainres.2007.05.047. [DOI] [PubMed] [Google Scholar]
- Schmitz C, et al. Cell. 2003;114:191–200. doi: 10.1016/s0092-8674(03)00556-7. [DOI] [PubMed] [Google Scholar]
- Shimizu T, et al. Pflügers Arch. 2009;457:795–807. doi: 10.1007/s00424-008-0558-6. [DOI] [PubMed] [Google Scholar]
- Smith GD, et al. Nature. 2002;418:186–190. doi: 10.1038/nature00894. [DOI] [PubMed] [Google Scholar]
- Story GM, et al. Cell. 2003;112:819–829. doi: 10.1016/s0092-8674(03)00158-2. [DOI] [PubMed] [Google Scholar]
- Ullrich ND, et al. Cell Calcium. 2005;37:267–278. doi: 10.1016/j.ceca.2004.11.001. [DOI] [PubMed] [Google Scholar]
- Vennekens R, et al. Nat Immunol. 2007;8:312–320. doi: 10.1038/ni1441. [DOI] [PubMed] [Google Scholar]
- Voets T, et al. J Biol Chem. 2004a;279:19–25. doi: 10.1074/jbc.M311201200. [DOI] [PubMed] [Google Scholar]
- Voets T, et al. Nature. 2004b;430:748–754. doi: 10.1038/nature02732. [DOI] [PubMed] [Google Scholar]
- Xu H, et al. Proc Natl Acad Sci USA. 2007;104:18321–18326. doi: 10.1073/pnas.0709096104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zurborg S, et al. Nat Neurosci. 2007;10:277–279. doi: 10.1038/nn1843. [DOI] [PubMed] [Google Scholar]
